Nina Babel

Researcher
The basics

Quick Facts

IntroResearcher
isResearcher
Work fieldAcademia
Gender
Female
Birth23 June 1971
Age53 years
Star signCancer
Education
Cleveland ClinicCleveland, Cuyahoga County, USA(2006—2007)
CharitéBerlin, Margraviate of Brandenburg, Germany(2004—2006)
Humboldt University of BerlinBerlin, Margraviate of Brandenburg, Germany(1990—1995)
Employers
Universitätsklinik Marien Hospital HerneHerne, Arnsberg Government Region, Germany
Ruhr University BochumBochum, Arnsberg Government Region, Germany(2015—)
Medical Library of the Charité – UniversitätsmedizinBerlin, Margraviate of Brandenburg, Germany(2014—)
Institute of Medical Immunology of the Charité BerlinGermany(2010—)
CharitéBerlin, Margraviate of Brandenburg, Germany(2003—)
Berlin Institute for Health ResearchBerlin, Margraviate of Brandenburg, Germany(2014—2015)
Medical Library of the Charité – UniversitätsmedizinBerlin, Margraviate of Brandenburg, Germany(2009—2015)
The details

Biography

Nina Babel, 2023

Nina Babel is a German physician and scientist. As a professor at Ruhr University Bochum and Charité, she treats patients and performs research in the field of immunodeficiencies and kidney diseases.

Life

Babel is the head of a research group focusing on immunology at the Charité. At Ruhr University Bochum, she heads the Center for Translational Medicine with a focus on immunology and transplantation at Marien Hospital Herne.

She studied medicine at Humboldt University of Berlin and completed her clinical training in the field of internal medicine, nephrology, and immunology at the Charité, where she also obtained her habilitation in 2008. As a Rahel Hirsch habilitation grant recipient, she carried out most of her habilitation work at the Charité and, from 2006 to 2007, as a fellow at the Taussig Cancer Center, Cleveland Clinic (Ohio).

Research and patient care

Babel's laboratory investigates mechanisms underlying the immunopathogenesis of viral diseases and develops new parameters and technologies to monitor the individual immune response and the risk of viral infection and virus-associated complications in immunocompromised patients.

Babel has led several research projects focusing on the host's immune response to SARS-CoV-2. For instance, the researchers discovered that individuals who had a severe course of COVID-19 did not exhibit a diminished immune response in comparison to those who had a mild course of the disease. In another study, it was observed that the development of antibodies after vaccination was lower with immunosuppressants than without, while the cellular immune response was preserved. According to this, patients can benefit from the vaccination despite their immunosuppressive therapy. Babel continues to work on the topics of Sars-CoV-2 immunity, and in particular Long Covid and chronic fatigue. Furthermore, her research topic includes analysis of interaction between host's immune response and herpes viruses such as Epstein–Barr virus.

Babel has been coordinator and principal investigator of several DFG and BMBF projects. She has an h-index of 53, has been involved in over 300 scientific publications, and is editor-in-chief for the Immunosuppression section of the journal Frontiers of Transplantation.

Young researchers support programs

Babel is actively involved in initiatives aimed at nurturing young researchers. Following her tenure as co-spokesperson of the SFB 650 Research Training Group at Charité from 2012 to 2016, she transitioned to Ruhr University Bochum, where she currently leads the RIMUR Research Training Group. In addition, Babel spearheads the Clinician Scientist Program at Ruhr University Bochum, securing funding from the DFG in the summer of 2022 to support this endeavor.

Publications (selection)

The contents of this page are sourced from Wikipedia article on 26 Nov 2024. The contents are available under the CC BY-SA 4.0 license.